• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮冠状动脉介入治疗左主干病变:糖尿病对死亡率的影响。

Percutaneous coronary intervention for left main stem disease: Impact of diabetes mellitus on mortality.

机构信息

Cardiology Department, James Cook University Hospital, Middlesbrough, UK.

Cardiology Department, Freeman Hospital, Newcastle upon Tyne, UK.

出版信息

Catheter Cardiovasc Interv. 2020 Oct 1;96(4):E416-E422. doi: 10.1002/ccd.28818. Epub 2020 Mar 5.

DOI:10.1002/ccd.28818
PMID:32134178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7687181/
Abstract

OBJECTIVES

We assessed the impact of diabetes mellitus (DM) on mortality after percutaneous coronary intervention (PCI) for left main stem (LMS) disease. Second, we compared mortality outcomes between non-insulin treated (NITDM) and insulin treated diabetes (ITDM) in different clinical settings.

BACKGROUND

There is a paucity of "real world" outcomes data in diabetic patients undergoing LMS PCI.

METHODS

We undertook a retrospective analysis of consecutive patients undergoing unprotected LMS PCI at 2 high volume tertiary centers. Diabetic status and clinical setting for PCI were recorded. The primary outcome measure was all-cause 30-day and long-term mortality (up to 36 months) post index PCI.

RESULTS

Between 2003 and 2017, 2,675 patients undergoing index LMS PCI were analyzed. Of those, 77.1% were non-DM, 15.8% NITDM, and 7.1% ITDM. Overall, DM status was not associated with higher 30-day mortality (OR 1.39, 95% CI 0.89-2.16, p = .15). During a median follow-up of 36 months, there was a borderline statistical association of DM with long-term mortality in all PCI settings (HR 1.31, 95% CI 1.00-1.71, p = .05). Compared to non-DM, ITDM but not NITDM was associated with short- and long-term mortality in all clinical presentations.

CONCLUSIONS

Overall, DM did not impact on 30-day mortality and had only a borderline statistical association with long-term mortality. It did not have an influence on mortality in non-emergency LMS PCI. The impact of DM on mortality outcomes following LMS PCI was only significant in the insulin treated patients.

摘要

目的

我们评估了糖尿病(DM)对左主干(LMS)疾病经皮冠状动脉介入治疗(PCI)后死亡率的影响。其次,我们比较了不同临床情况下非胰岛素治疗(NITDM)和胰岛素治疗糖尿病(ITDM)患者的死亡率结果。

背景

在接受 LMS PCI 的糖尿病患者中,“真实世界”结果数据很少。

方法

我们对在 2 家高容量三级中心接受非保护 LMS PCI 的连续患者进行了回顾性分析。记录了糖尿病状态和 PCI 的临床情况。主要观察指标是所有原因的 30 天和长期死亡率(最长 36 个月)。

结果

在 2003 年至 2017 年间,分析了 2675 例接受 LMS PCI 的患者。其中,77.1%为非 DM,15.8%为 NITDM,7.1%为 ITDM。总体而言,DM 状态与 30 天死亡率升高无关(OR 1.39,95%CI 0.89-2.16,p =.15)。在中位数为 36 个月的随访期间,DM 与所有 PCI 情况下的长期死亡率存在统计学关联(HR 1.31,95%CI 1.00-1.71,p =.05)。与非 DM 相比,在所有临床表现中,ITDM 而非 NITDM 与短期和长期死亡率相关。

结论

总体而言,DM 不会影响 30 天死亡率,仅与长期死亡率存在统计学关联。它对非紧急 LMS PCI 的死亡率没有影响。DM 对 LMS PCI 后死亡率结果的影响仅在胰岛素治疗患者中显著。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede7/7687181/9f6d64809d0b/CCD-96-E416-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede7/7687181/8a2aa1d41270/CCD-96-E416-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede7/7687181/9f6d64809d0b/CCD-96-E416-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede7/7687181/8a2aa1d41270/CCD-96-E416-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ede7/7687181/9f6d64809d0b/CCD-96-E416-g002.jpg

相似文献

1
Percutaneous coronary intervention for left main stem disease: Impact of diabetes mellitus on mortality.经皮冠状动脉介入治疗左主干病变:糖尿病对死亡率的影响。
Catheter Cardiovasc Interv. 2020 Oct 1;96(4):E416-E422. doi: 10.1002/ccd.28818. Epub 2020 Mar 5.
2
Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus.经皮冠状动脉血运重建术后的死亡率:既往心血管危险因素控制与糖尿病患者预后改善
Catheter Cardiovasc Interv. 2017 Jun 1;89(7):1195-1204. doi: 10.1002/ccd.26882. Epub 2016 Dec 28.
3
Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI.与无糖尿病患者相比,经胰岛素治疗和未经胰岛素治疗的糖尿病对当代经皮冠状动脉介入治疗(PCI)后 1 年结局的影响。
Catheter Cardiovasc Interv. 2020 Aug;96(2):298-308. doi: 10.1002/ccd.28841. Epub 2020 Mar 12.
4
Significance of diabetes mellitus status in patients undergoing percutaneous left main coronary artery intervention.糖尿病患者行经皮左主干冠状动脉介入治疗的意义。
Catheter Cardiovasc Interv. 2024 Oct;104(4):723-732. doi: 10.1002/ccd.31179. Epub 2024 Aug 17.
5
Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus.胰岛素治疗与非胰岛素治疗的糖尿病患者接受ST段抬高型心肌梗死直接经皮冠状动脉介入治疗后的长期死亡率。
EuroIntervention. 2014 May;10(1):90-6. doi: 10.4244/EIJV10I1A15.
6
Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial.经皮冠状动脉介入治疗(PCI)与冠状动脉旁路移植术(CABG)治疗糖尿病患者的长期疗效比较:来自 FREEDOM 试验的结果。
J Am Coll Cardiol. 2014 Sep 23;64(12):1189-97. doi: 10.1016/j.jacc.2014.06.1182.
7
Coronary artery bypass surgery compared with percutaneous coronary interventions in patients with insulin-treated type 2 diabetes mellitus: a systematic review and meta-analysis of 6 randomized controlled trials.胰岛素治疗的2型糖尿病患者冠状动脉搭桥手术与经皮冠状动脉介入治疗的比较:6项随机对照试验的系统评价和荟萃分析
Cardiovasc Diabetol. 2016 Jan 6;15:2. doi: 10.1186/s12933-015-0323-z.
8
The impact of diabetes on the prognostic value of left ventricular function following percutaneous coronary intervention: Insights from the British Cardiovascular Intervention Society.糖尿病对经皮冠状动脉介入治疗后左心室功能预后价值的影响:来自英国心血管介入学会的见解。
Catheter Cardiovasc Interv. 2018 Nov 15;92(6):E393-E402. doi: 10.1002/ccd.27642. Epub 2018 May 4.
9
Outcomes in Patients with Diabetes Mellitus According to Insulin Treatment After Percutaneous Coronary Intervention in the Second-Generation Drug-Eluting Stent Era.第二代药物洗脱支架时代经皮冠状动脉介入治疗后根据胰岛素治疗情况的糖尿病患者结局
Am J Cardiol. 2018 Jun 15;121(12):1505-1511. doi: 10.1016/j.amjcard.2018.02.034. Epub 2018 Apr 18.
10
Diabetes Mellitus and Long-Term Risk for Heart Failure After Coronary Revascularization.糖尿病与冠状动脉血运重建后心力衰竭的长期风险。
Circ J. 2020 Feb 25;84(3):471-478. doi: 10.1253/circj.CJ-19-0980. Epub 2020 Jan 29.

引用本文的文献

1
Treatment of Left Main Disease: Let the Patient Choose.左主干病变的治疗:让患者做出选择。
J Am Heart Assoc. 2021 Jul 20;10(14):e021990. doi: 10.1161/JAHA.121.021990. Epub 2021 Jul 9.

本文引用的文献

1
Diabetes in Myocardial Revascularization for Left Main Coronary Artery Disease: Predictor or Decision Maker?左主干冠状动脉疾病心肌血运重建中的糖尿病:预测因素还是决策因素?
J Am Coll Cardiol. 2019 Apr 9;73(13):1629-1632. doi: 10.1016/j.jacc.2019.02.005.
2
Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes.左主干病变伴糖尿病患者行旁路移植术或支架置入术治疗的比较
J Am Coll Cardiol. 2019 Apr 9;73(13):1616-1628. doi: 10.1016/j.jacc.2019.01.037.
3
'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization.
2018年欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南的“十诫”
Eur Heart J. 2019 Jan 7;40(2):79-80. doi: 10.1093/eurheartj/ehy855.
4
Impact of diabetes mellitus in patients undergoing contemporary percutaneous coronary intervention: Results from a Korean nationwide study.糖尿病患者行当代经皮冠状动脉介入治疗的影响:一项来自韩国全国性研究的结果。
PLoS One. 2018 Dec 10;13(12):e0208746. doi: 10.1371/journal.pone.0208746. eCollection 2018.
5
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.SGLT2 抑制剂用于 2 型糖尿病的心血管和肾脏结局的一级和二级预防:心血管结局试验的系统评价和荟萃分析。
Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.
6
Obstructive left main stem coronary disease: is it time to recommend coronary stenting?阻塞性左主干冠状动脉疾病:是时候推荐冠状动脉支架置入术了吗?
Heart. 2018 Apr;104(7):614-620. doi: 10.1136/heartjnl-2016-310880. Epub 2017 Oct 23.
7
Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials.SYNTAX 评分 I 和 II 对合并多支血管病变糖尿病患者的影响:SYNTAX、PRECOMBAT 和 BEST 试验患者水平数据的汇总分析。
Eur Heart J. 2017 Jul 1;38(25):1969-1977. doi: 10.1093/eurheartj/ehx138.
8
Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus.经皮冠状动脉血运重建术后的死亡率:既往心血管危险因素控制与糖尿病患者预后改善
Catheter Cardiovasc Interv. 2017 Jun 1;89(7):1195-1204. doi: 10.1002/ccd.26882. Epub 2016 Dec 28.
9
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.依维莫司洗脱支架或旁路移植术治疗左主干冠状动脉疾病。
N Engl J Med. 2016 Dec 8;375(23):2223-2235. doi: 10.1056/NEJMoa1610227. Epub 2016 Oct 31.
10
Changes in diabetes-related complications in the United States, 1990-2010.美国 1990-2010 年糖尿病相关并发症的变化。
N Engl J Med. 2014 Apr 17;370(16):1514-23. doi: 10.1056/NEJMoa1310799.